Jim Cramer on BillionToOne: “I Say Buy It”

BillionToOne, Inc. (NASDAQ:BLLN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. Toward the end of the lightning round, a caller sought Cramer’s opinion on the stock, and he commented:

We like BillionToOne. We looked at it, we thought the name was so silly… But it’s a real company… That’s going to be very good. I say buy it.

Stock market data. Photo by Photo by Alesia Kozik

BillionToOne, Inc. (NASDAQ:BLLN) develops precision molecular diagnostics using a platform that counts DNA molecules to improve disease detection. The company’s tests include non-invasive prenatal screening and liquid biopsies to detect and monitor cancer mutations. Cramer was bullish on the stock when a caller inquired about the stock during the April 27 episode, as he commented:

We looked into BillionToOne. We think it’s a really good diagnostic company. Now, the diagnostic companies themselves have been going down, whether it be Becton, Dickinson, whether it be Abbott Labs, they’ve not been working. That said, this stock never ran to begin with. I think BillionToOne’s a winner.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.